- Home
- SGLY vs IMNN Comparison
SGLY vs IMNN Comparison
Compare SGLY & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | IMNN |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 12.9M |
| IPO Year | 2008 | 1985 |
Fundamental Metrics
Financial Performance| Metric | SGLY | IMNN |
|---|---|---|
| Price | $0.54 | $3.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 38.1K | 33.6K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,619,679.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $3.56 |
| 52 Week High | $5.49 | $41.22 |
Technical Indicators
Market Signals| Indicator | SGLY | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 38.96 |
| Support Level | $0.56 | $3.80 |
| Resistance Level | $0.60 | $4.00 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).